THE FOLLOWING WERE APPROVED

INVESTIGATOR: Daniel Smith PhD
6330 San Vicente Blvd.
Suite 401
Los Angeles, California  90048

BOARD ACTION DATE: 06/05/2014
PANEL: 3

STUDY APPROVAL EXPIRES: 06/16/2015
STUDY NUM: 1059003
WIRB PRO NUM: 20040881
INVEST NUM: 191659
WO NUM: 1-837198-1
CONTINUING REVIEW: Annually
SITE STATUS REPORTING: Annually

SPONSOR: National Institute of Mental Health

PROTOCOL NUM: None

AMD. PRO. NUM: None

TITLE: AUTISM GENETIC RESOURCE EXCHANGE (AGRE)

APPROVAL INCLUDES:
Investigator
Revised Protocol (05-28-2014)

WIRB APPROVAL IS GRANTED SUBJECT TO:

WIRB HAS APPROVED THE FOLLOWING LOCATIONS TO BE USED IN THE RESEARCH:
Autism Genetic Resource Exchange/Autism Speaks, 6330 San Vicente Blvd., Suite 401, Los Angeles, California  90048

If the PI has an obligation to use another IRB for any site listed above and has not submitted a written statement from the other IRB acknowledging WIRB's review of this research, please contact WIRB's Client Services department.

ALL WIRB APPROVED INVESTIGATORS MUST COMPLY WITH THE FOLLOWING:

1. Conduct the research in accordance with the protocol, applicable laws and regulations, and the principles of research ethics as set forth in the Belmont Report.

2. Although a participant is not obliged to give his or her reasons for withdrawing prematurely from the clinical trial, the investigator should make a reasonable effort to ascertain the reason, while fully respecting the participant’s rights.

3. Unless consent has been waived, conduct the informed consent process without coercion or undue influence, and provide the potential subject sufficient opportunity to consider whether or not to participate. (Due to the unique circumstances of research conducted at international sites outside the United States and Canada where WIRB approved materials are translated into the local language, the following requirements regarding consent forms bearing the WIRB approval stamp and regarding certification of translations are not applicable.)
   a. Use only the most current consent form bearing the WIRB "APPROVED" stamp.
   b. Provide non-English speaking subjects with a certified translation of the approved consent form in the subject's first language. The translation must be approved by WIRB unless other arrangements have been made and approved by WIRB.
   c. Obtain pre-approval from WIRB for use of recruitment materials and other materials provided to subjects.

IF YOU HAVE ANY QUESTIONS, CONTACT WIRB AT 1-800-562-4789

This is to certify that the information contained herein is true and correct as reflected in the records of the Western Institutional Review Board (WIRB), OHRP/FDA parent organization number IORG 0000432, IRB registration number IRB00000533. WE CERTIFY THAT WIRB IS IN FULL COMPLIANCE WITH GOOD CLINICAL PRACTICES AS DEFINED UNDER THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) REGULATIONS, AND THE INTERNATIONAL CONFERENCE ON HARMONISATION (ICH) GUIDELINES.
4. Enrollment of limited readers and non-readers: unless consent has been waived or the protocol excludes enrollment of limited readers or non-readers, involve an impartial witness in the consent process when enrolling limited or non-readers and document the participation of the impartial witness using the designated signature lines on the WIRB-approved consent form. In the absence of designated signature lines, download the WIRB standard impartial witness form from www.wirb.com.

5. Obtain pre-approval from WIRB for changes in research.

6. Obtain pre-approval from WIRB for planned deviations and changes in research activity as follows:
   - If the research is federally funded, conducted under an FWA, or is a clinical investigation of a drug or biologic, then all planned protocol deviations must be submitted to WIRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects [(DHHS 45 CFR § 46.103(b)(4); (FDA 21 CFR § 56.108(a)(4); ICH 3.3.7].
   - However, if the research is a clinical investigation of a device and the research is not federally funded and not conducted under an FWA, then only planned protocol deviations that may adversely affect the rights, safety or welfare of subjects or the integrity of the research data should be submitted to WIRB for review and approval prior to implementation except where necessary to eliminate apparent immediate hazards to the human subjects [(DHHS 45 CFR § 46.103(b)(4); (FDA 21 CFR § 56.108(a)(4); ICH 3.3.7].

The reason for these different requirements regarding planned protocol deviations is that the Office for Human Research Protections (OHRP) and the Food and Drug Administration (FDA) drug and biologic divisions have adopted the regulatory interpretation that every planned protocol deviation is a change in research that needs prior IRB review and approval before implementation; however, the FDA device division operates under a distinct regulation (See 21 CFR 812.150(a)(4).

Deviations necessary to eliminate apparent immediate hazards to the human subjects should be reported within 10 days.

7. Report the following information items to the IRB within 5 days:
   a. New or increased risk
   b. Protocol deviation that harmed a subject or placed subject at risk of harm
   c. Protocol deviation made without prior IRB approval to eliminate an immediate hazard to a subject
   d. Audit, inspection, or inquiry by a federal agency
   e. Written reports of federal agencies (e.g., FDA Form 483)
   f. Allegation of Noncompliance or Finding of Noncompliance
   g. Breach of confidentiality
   h. Unresolved subject complaint
   i. Suspension or premature termination by the sponsor, investigator, or institution
   j. Incarceration of a subject in a research study not approved to involve prisoners
   k. Adverse events or IND safety reports that require a change to the protocol or consent
   l. State medical board actions
   m. Unanticipated adverse device effect
   n. Information where the sponsor requires prompt reporting to the IRB

Information not listed above does not require prompt reporting to WIRB.

Please go to www.wirb.com for complete definitions and forms for reporting.

8. Provide reports to WIRB concerning the progress of the research, when requested.

9. Ensure that prior to performing study-related duties, each member of the research study team has had training in the protection of human subjects appropriate to the processes required in the approved protocol.

Federal regulations require that WIRB conduct continuing review of approved research. You will receive Continuing Review Report forms from WIRB. These reports must be returned even though your study may not have started.

DISTRIBUTION OF COPIES:

Contact, Company
Shanise Owens, Autism Genetic Resource Exchange (AGRE)
Scott Newman, Autism Genetic Resource Exchange (AGRE)
Daniel Smith PhD, Autism Genetic Resource Exchange (AGRE)